Lonsurf and Lung disorder - a phase IV clinical study of FDA data

Summary:

Lung disorder is reported as a side effect among people who take Lonsurf (tipiracil hydrochloride; trifluridine), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Stivarga, and have Colon cancer.

The phase IV clinical study analyzes which people have Lung disorder when taking Lonsurf. It is created by eHealthMe based on reports of 10,075 people who have side effects when taking Lonsurf from the FDA, and is updated regularly.

What is Lonsurf?

Lonsurf has active ingredients of tipiracil hydrochloride; trifluridine. eHealthMe is studying from 10,077 Lonsurf users. Check the latest studies of Lonsurf.

What is Lung disorder?

Lung disorder (lung disease) is found to be associated with 1,799 drugs and 1,787 conditions by eHealthMe. Check the latest studies of Lung disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

10,075 people reported to have side effects when taking Lonsurf.
Among them, 20 people (0.2%) have Lung disorder.

Among these 20 people:

How long have people been on Lonsurf when they have Lung disorder? *

What is the gender of people who have Lung disorder when taking Lonsurf? *

female: 63.16 %
male: 36.84 %

What is the age of people who have Lung disorder when taking Lonsurf? *

What are other drugs people take besides Lonsurf? *

What are other side effects people have besides Lung disorder? *

Fatigue (feeling of tiredness): 9 people, 45.00%
Constipation: 8 people, 40.00%
White Blood Cell Count Decreased: 7 people, 35.00%
Nausea (feeling of having an urge to vomit): 6 people, 30.00%
Disease Progression: 6 people, 30.00%
Dental Caries: 5 people, 25.00%
Nausea And Vomiting: 5 people, 25.00%
Dry Mouth: 5 people, 25.00%
Red Blood Cell Count Abnormal: 5 people, 25.00%
Fever: 4 people, 20.00%

What are the existing conditions these people have? *

Rectal Cancer (cancer of rectum): 6 people, 30.00%
Colon Cancer: 6 people, 30.00%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 3 people, 15.00%
Neuropathy Peripheral (surface nerve damage): 2 people, 10.00%
High Blood Pressure: 2 people, 10.00%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 2 people, 10.00%
Rectosigmoid Cancer (cancer that originates in the rectum and sigmoid colon): 1 person, 5.00%
Rectal Cancer Metastatic (cancer of rectum spreads to other): 1 person, 5.00%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lonsurf and have Lung disorder?

- Check whether Lung disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lonsurf:

Lonsurf (10,077 reports)

Lung disorder treatments and more:

Lung disorder (66,567 reports)

How severe was Lung disorder and when was it recovered:

Lung disorder in Lonsurf

Expand to all the drugs that have ingredients of tipiracil hydrochloride; trifluridine:

Lung disorder and drugs with ingredients of tipiracil hydrochloride; trifluridine

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lonsurf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lung disorder:

Lung disorder (1,799 drugs)

Browse all the conditions that are associated with Lung disorder:

Lung disorder (1,787 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tipiracil hydrochloride; trifluridine (the active ingredients of Lonsurf) and Lonsurf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.